What is Zacks Small Cap’s Estimate for CYCN FY2025 Earnings?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) – Equities research analysts at Zacks Small Cap issued their FY2025 earnings per share (EPS) estimates for shares of Cyclerion Therapeutics in a report issued on Monday, February 2nd. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings of ($1.34) per share for the year. Zacks Small Cap also issued estimates for Cyclerion Therapeutics’ Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.20) EPS and FY2027 earnings at ($0.99) EPS.

Cyclerion Therapeutics (NASDAQ:CYCN) last announced its quarterly earnings results on Thursday, October 30th. The company reported ($0.30) EPS for the quarter. Cyclerion Therapeutics had a negative net margin of 77.02% and a negative return on equity of 24.61%. The company had revenue of $0.88 million for the quarter.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Cyclerion Therapeutics has an average rating of “Sell”.

Cyclerion Therapeutics Stock Performance

NASDAQ CYCN opened at $1.24 on Thursday. Cyclerion Therapeutics has a 1 year low of $1.16 and a 1 year high of $5.18. The company has a fifty day simple moving average of $1.49 and a 200 day simple moving average of $2.01. The company has a market cap of $4.87 million, a P/E ratio of -1.65 and a beta of 0.98.

Hedge Funds Weigh In On Cyclerion Therapeutics

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.